Literature DB >> 11986282

Effect of contaminating red blood cells on OKT3-mediated polyclonal activation of peripheral blood mononuclear cells.

Samuel Song1, Joseph Goodwin, Jenny Zhang, Bruce Babbitt, Janet L Lathey.   

Abstract

Erythrocytes are typically present as impurities in the majority of peripheral blood mononuclear cell (PBMC) preparations. This study was undertaken to investigate the effects of contaminating red blood cells (RBC) on the ability of OKT3 to activate CD4(+) and CD8(+) T cells. Surprisingly, the levels of gamma interferon, tumor necrosis factor alpha, and interleukin-1 beta (IL-1 beta) produced by PBMC upon stimulation by OKT3 were increased (P < 0.05) in a dose-dependent manner when increasing amounts of autologous RBC (RBC-to-PBMC ratios of 2:1, 10:1, and 50:1) were spiked into PBMC preparations. The OKT3-driven induction of the IL-2 receptor (CD25) and the proliferation of T lymphocytes in response to phorbol myristate acetate were not affected by the addition of RBC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986282      PMCID: PMC119986          DOI: 10.1128/cdli.9.3.708-712.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  6 in total

1.  Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry.

Authors:  M A Suni; L J Picker; V C Maino
Journal:  J Immunol Methods       Date:  1998-03-01       Impact factor: 2.303

2.  In vitro production of interleukin-2 by lymphocytes in whole blood and isolated culture.

Authors:  M Lyte
Journal:  J Clin Lab Immunol       Date:  1988-08

3.  Adoptive cellular therapy of human breast and colorectal tumor targets using ex vivo activated memory T lymphocytes with potentiation by cis-diamminedichloroplatinum(II).

Authors:  J E Gold; I J Bleiweiss; A B Goldfarb; J J Bauer; I M Gelernt; M E Schwartz; M A Reiner; C M Miller; M F Weiss; S T Brower
Journal:  J Surg Oncol       Date:  1994-04       Impact factor: 3.454

4.  Preliminary validation of an activation assay for ex vivo activated T cells utilized in cancer immunotherapy.

Authors:  D Hamilton; J Goodwin; M B Clarke; G C du Moulin; V Liu; B Caplan; B Babbitt
Journal:  Biotechnol Bioeng       Date:  1994-04-05       Impact factor: 4.530

5.  Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human soft-tissue sarcoma targets with potentiation by cis-diamminedichloroplatinum(II).

Authors:  J E Gold; T R Masters; N D Bloom; M K Shafir; M J Klein; S Kenan; M E Osband
Journal:  J Surg Oncol       Date:  1995-04       Impact factor: 3.454

6.  Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma.

Authors:  M E Osband; P T Lavin; R K Babayan; S Graham; D L Lamm; B Parker; I Sawczuk; S Ross; R J Krane
Journal:  Lancet       Date:  1990-04-28       Impact factor: 79.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.